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Abstract
Genetic defects play a major role in pathogenesis of the most of haematological 
malignancies, including cytogenetic abnormalities, gene mutations, and abnormal 
gene expression. Our knowledge about the genetics of haematological disorders has 
been dramatically improved during the past decade, due to revolution of sequenc-
ing technologies which have played a crucial role. In this chapter, we describe the 
techniques commonly employed for elucidating chromosomal aberrations, prog-
nostic impact of recurrent chromosomal abnormalities, and recently updated risk 
stratification systems. We will summarise the chromosomal abnormalities recently 
identified on many of haematological diseases such acute myeloid leukaemia, acute 
lymphoid leukaemia, myelodysplasic syndrome, multiple myeloma, meylopro-
liferative disease and clarify their impacts on clinical phenotype and prognosis, 
as well as their role in the pathogenesis of these diseases. The aim of this chapter 
is to provide a brief overview of the recent progresses in haematological diseases 
genetics.
Keywords: clonal evolution, cytogenetic, somatic mutation, chromosomal 
abnormality, WHO classification
1. Introduction
The few recent years seen revolution on genetic technic with a big improvement 
of new technology. Haematological malignancy benefits from this development. 
Geneticists cooperate closely with hemato-oncologists; this cooperation improves 
many aspect of hemato-oncologists practice. It s can be helpful for diagnostic tests 
but also the key its allow also a better knowledge of cancer genetics which helps 
the specialist assess prognosis of their patient, selection of the most appropriate 
anticancer therapy, and monitoring the response to treatment [1].
Cytogenetic techniques occupied an important place in haematological diag-
nostics. The first chromosomal aberration described was in 1960 by Nowel and 
Hungeford characteristic, it was about CML- Philadelphia chromosome, few years 
after, it was be proved that almost every haematological neoplasm possess was 
associated with karyotype abnormalities [2].
ON 1980s, new method was developed: fluorescence in situ hybridization 
(FISH), it s characterised by high sensitivity and specificity, this technic has an 
other major particularity, it can be performed rapidly, and can classified the nature 
of chromosomal abnormalities [3].
Cytogenetics - Classical and Molecular Strategies for Analysing Heredity Material
2
Over the last few years, more powerful technologies were developed, the most 
remarkable one is was the Next-generation sequencing (NGS) witch was a real 
revolution on haematology [4].
In this chapter, we describe the techniques commonly employed for elucidating 
chromosomal aberrations, prognostic impact of recurrent chromosomal abnor-
malities, and recently updated risk stratification systems.
We will summaries the chromosomal abnormalities recently identified on many 
of haematological diseases such acute myeloid leukaemia, acute lymphoid leukaemia, 
myelodysplasic syndrome, multiple myeloma, meyloproliferative disease and clarify 
their impacts on clinical phenotype and prognosis, as well as their role in the patho-
genesis of these diseases.
The aim of this chapter is to provide a brief overview of the recent progresses in 
haematological diseases genetics.
2. Cytogenetic technic
Cytogenetic study plays a crucial role on haematology, its the main outil for 
making diagnosis for almost all haematological malignancies, and its have an 
important impact prognosis for those diseases, and cytogenetic abnormalities are 
included on almost all prognosis score and risk stratifications for haematological 
neoplasms.
The past several years’ remarkable efforts were deployed for better understand-
ing of genetics and genome biology, many new technologies were developed, and 
the old technic saw improved their sensibility and specificity.
Veritable revolution was seen thanks to NGS, this technic offers possibility of 
broad analysis of a genome by whole-genome sequencing (WGS), exome sequencing, 
transcriptome sequencing, and epigenomics [5].
2.1 Conventional cytogenetic
Cytogenetic analyse in hematologicl neoplasms is performed by bone marrow 
aspiration in sterile way with heparine filled probes.
Sometimes, katyotype can be realised by peripheral blood.
The Celle of aspirated bonne marrow are cultured in vitro, then microscopic 
slides with metaphases chromosomes and/or interphase nuclei is performed.
Karyotype needs many metaphases cell (20 to 30) to be significatif, so its 
required time [2].
Conventional cytogenetics still be the most frequently ordered genetic test for 
various leukaemias, most prominently chronic myelogenous leukaemia (CML) in a 
resource limited situation.
2.2 Fluorescence in situ hybridization (FISH)
FISH is the best alternative to karyotype, it is rapid technic, with high level of 
specificity and sensibility. It can be realised from bone marrow or peripheral blood, 
it can also be performed from fixed and sectioned tissue [3].
FISH constitues a big step for studying somatic chromosomal mosaicism 
and molecular cytogenetic detection of chromosomal variations in interphase 
nuclei [6, 7].
FISH is a molecular cytogenetic technique, it identifies chromosomal abnor-
malities using molecular technology.
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Technic of FISH is based on A DNA probe is tagged with a fluorescent marker. 
The probe and target DNA are denatured, and the probe is allowed to hybridise with 
the target. The fluorescent tag is then detected with a fluorescent microscope.
2.3 Polymerase chain reaction (PCR)
PCR is a technique that involves amplification of a desired segment of DNA by 
using primers, nucleotides and enzymes like reverse transcriptase and DNA poly-
merases. It represents the most used molecular technique on haematology. Different 
types of PCRs exist. Reverse transcriptase PCR (RT-PCR), Real time PCR (RQ-PCR).
In clinical practice RQ PCR is commonly used for viral copies detection and 
specific gene detection like Bcr-abl and PML-RARA for assessment of treatment 
response [1] new technique was developted: Digital PCR it s used for DNA/RNA 
detection and quantification. It is emerging as an alternative to conventional 
RQ-PCR for quantification and low abundance mutation detection [8].
PCR have many applications in hematologic malignancies include. it s used for 
detection of fusion genes and mutations. Its also performed for analysing of post 
transplant chimerism, and can be realised for determination of lymphoid clonality.
2.4 Genome-wide arrays
Microarray based testing such as array comparative genomic hybridization 
(CGH) and single nucleotide polymorphisms (SNP) arrays are now more used in 
routine diagnostics for haematological malignancies.
The copy numbers of DNA sequences in the test and reference samples are 
quantified by assessment of relative fluorescence intensities detected by digital 
imaging systems.
2.5 Gene expression profiling
This technique is based on DNA microarray which utilises plates which have 
various complementary genetic sequence covalently attached to them.
At present availability of GEP is limited to few research centers only limiting its 
wide use in clinical practice.
2.6 New generation sequencing
Over the past few years, an important increasing of the use of NGS on haematol-
ogy have been shown, new platforms are available and are very helpful to identify 
the genetic basis of haematological neoplasms and genome biology.
Next-generation sequencing (NGS) encompasses several different methodolo-
gies that allow the investigation of genomics, transcriptomics and epigenomics [4].
Application of NGS in hematologic malignancies has confirmed presence of a lot 
of mutation of certain genes like TP53, ATM, RAS etc. the inconvenient for NGS, 
its the cost, this technic still expensive and can not be used on large spectre today 
especially for limited resource’s country.
3. Haematological malignancies applications
Haematological neoplasms benefits from progress of biological technology, the 
use of new platforms helps to approve the performance of identification of genetic 
abnormalities.
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This knowledge is crucial and have clinical utility, it can also improve diagnos-
tics, prognosis, monitoring of minimal residual disease and it can be helpful to 
target of dysregulated signalling pathways by specific therapeutic targets [4].
We will summaries the chromosomal abnormalities recently identified on many 
of haematological diseases such acute myeloid leukaemia, acute lymphoid leukaemia, 
myelodysplasic syndrome, multiple myeloma, chronic lymphoblastic leukaemia, 
meyloproliferative disease and clarify their impacts on clinical phenotype and 
prognosis, as well as their role in the pathogenesis of these diseases.
3.1 Acute myeloid leukaemia (AML)
Cytogenetic abnormalities are frequently reported in the literature describing 
the presence of chromosomal rearrangements in important cases of acute myeloid 
leukaemia (AML): the rate can reach 50–60% of cases of AML [9].
It has been proved that AML is a complex and evaluative disease [10, 11]. There 
are many leukaemia genes, most of which are infrequently mutated, and patients 
typically have more than one driver mutation. The AML evolved over time, with 
multiple competing clones coexisting at any time [10, 11].
Over the few recent years, genome biology have seen a veritable revolution of 
technology, including chromosome banding, with fluorescence/chromosome in situ 
hybridization, or other analyses like array comparative network genomic hybridiza-
tion, genome breakpoints cloning and Sanger Sequencing of candidate genes and 
profiling of single nucleotide polymorphism, and even whole-genome sequencing 
(WGS), whole-exome sequencing (WES), and RNA sequencing have all contrib-
uted to incremental improvements in understanding the genetic basis of the AML.
The whole-genome sequencing for AML showed that it is an evaluative and 
complex disease. There are many leukemia genes, most of which are infrequently 
mutated, and patients typically have many driver mutations. The evolution is char-
acterized by emergence of many competing clones which can coexist at any time.
In fact, it has been proved that different genes and clones coexisting in the same 
patient, Figure 1 illustrates that clearly [12].
200 AML patients has been analysed by The Cancer Genome Atlas (TCGA) 
consortium, they use whole-genome or whole-exome sequencing and they 
identified 23 genes as “significantly mutated” at a higher-than-expected fre-
quency [13].
Conventional cytogenetics is very important on AML, it identifies chromosomal 
abnormalities, it can be balanced transloca tions, inversions, insertions, monoso-
mies, and trisomies, which are present in approximately 55% of adult cases and 
80% of children with AML. These are the strongest prognostic factors for response 
to treatment and survival in multivariate analysis. The 2008 WHO classification 
categorized AML based on cytogenetic or molecular abnormalities [14, 15].
The WHO 2008 and 2016 classifications incorporated modifications that 
allowed for a greater number of patients to be classified into the category of AML 
[16, 17].
Even patient with normal karyotype AML, it has been proved recently with 
certitude that those patients constituted very heterogeneous group; new technology 
helps to identified many gene mutations in normal karyotype AML by cutting-edge 
next-generation sequencing NGS technology, like FLT3-ITD, NPM1, CEBPA, and 
other additional mutations.
The most important predictors of shorter overall survival in AML patients aged 
less than 60 years are represented by DNMT3A and RUNX1 mutations especially 
those with intermediate-risk cytogenetic.
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NPM1 mutations were also considered as important molecular prognosticators 
of Overall Survivor, particularly in the absence of FLT3-ITD, mutated TP53, and 
bi-allelic CEBPA mutations.
Actually, for treating patient with AML, it is indispensable to perform the 
research of these gene mutations. It s important for diagnosis and it can be helpful 
as molecular marker of prognosis, and its necessary to predictive for response of 
treatment, and used also for disease monitoring.
Studies demonstrated that patients with cytogenetically normal AML or 
intermediate-risk abnormalities have more additional gene mutations than patients 
with favourable or unfavourable abnormal cytogenetic and especially those with 
balanced translocations [18].
Recent research showed that aged patients have more driver gene mutations than 
younger patients. Its seems that elderly patients have more alterations in specific 
genes including TET2, RUNX1, ASXL1, and SRSF2. All this gene has recently been 
implicated in age-related clonal haematopoiesis. These found participate to improve 
our understanding of knowledge in AML biology between younger and older 
patients [19].
The application for biological technology such NSG are multiple, for exemple, 
there are a number of FLT3 inhibitors at various stages of clinical development 
were produced, such as PKC412 (midostaurin), CEP-701 (lestaurtinib), or MLN518 
(tandutinib).
TKIs are promising agents in the treatment of AML patients with an FLT3-ITD 
mutation, especially when they are combined with chemotherapy [20].
3.2 Acute lymphoblastic leukaemia (ALL)
Acute lymphoblastic leukaemia (ALL) is the most often childhood neoplasm 
occuring about 30% of all cancer.
Figure 1. 
Molecular classes of AML and concurrent gene mutations in adult patients up to the age of ~65 years. For 
each AML class denoted in the pie chart, frequent co-occurring mutations are shown in the respective boxes. 
Data on the frequency of genetic lesions are compiled from the databases of the British Medical Research 
Council (MRC) and the German-Austrian AML study group (AMLSG) and from selected studies. It 
indicates cohesin genes including RAD21 (10%), SMC1A (5%), and SMC3 (5%); inv(16)(p13.1q22) or 
t(16;16)(p13.1;q22); CBFB-MYH11; and inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1), 
and TP53 mutations are found in 45% and complex karyotypes in 70% of this class.
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Abnormalities in chromosome number as well as structural rearrangements 
(translocations) are detected in 60–80% of patients with ALL, whereas the remain-
ing 20–40% have a normal karyotype [21, 22].
Improvement of cytogenetic, FISH, and reverse transcription polymerase chain 
reaction (RT-PCR) analyses permits to identify subgroups of acute lymphoblastic 
leukaemia with specific chromosome abnormalities and allow determining treatment 
strategy for childhood ALL, especially when specific aberrations are present [23, 24].
Recurrent genetic abnormalities have been identified on ALL, including bal-
anced translocations and aneuploidies. Based on the World Health Organization 
(WHO) classification, BCP-ALL is categorized into ALL with hyperdiploidy 
(>50 chromosomes), ALL with hypodiploidy (<44 chromosomes), and ALL with 
translocation t(9;22) (q34;q11.2) encoding BCR–ABL1, t(12;21) (p13;q22) encoding 
TEL–AML1, t(1;19) (q23;p13.3) encoding E2A–PBX1, t(5;14) (q31;q32) encoding 
IL3–IGH, and rearrangement of MLL at 11q23, with a diverse range of partner genes 
[25, 26].
Concerning T- ALL, common alterations include rearrangement of the T-cell 
receptor gene loci to transcription factor genes including TLX1, TLX3, LYL1, TAL1, 
and MLL [27].
ALL genomes are not static but exhibit acquisition of new chromosomal abnor-
malities over time. Single-nucleotide polymorphism microarray profiling studies 
of matched diagnosis–relapse ALL samples show that most ALL cases exhibit 
changes in the patterns of structural genomic alterations from diagnosis to relapse 
and that many relapse-acquired lesions, including those targeting genes associated 
with high-risk ALL (IKZF1, IKZF2, CDKN2A, and CDKN2B), are detectable at the 
diagnosis [28, 29].
3.3 Myelodysplasic syndrome
Myelodysplasia syndromes (MDS) are defined by a heterogeneous group of 
myeloid malignancies characterised by peripheral blood cytopenia and dishemato-
poiesis and frequently progress to acute myeloid leukaemia.
The 2016 revision defines 10 MDS subtypesas follows:
• MDS with single lineage dysplasia (MDS-SLD),
• MDS with dysplasia in two or more myeloid lineages (MDS-MLD),
• MDS-SLD/MLD with ≥15% ring sideroblasts (RSs; MDS-MLD-RS),
• MDS with an excess of blasts of up to 9% in bone marrow and up to 4% in 
peripheral blood (MDSEB- 1),
• MDS with 10%–19% bone marrow and 5%–19% blood blasts (MDS-EB-2),
• MDS with isolated deletion of chromosome 5q [del(5q)]
• MDS unclassifiable (MDS-U) based on defining cytogenetic abnormality, 
MDS-U with SLD and pancytopenia and MDS-U with 1% blood blasts.
Conventional cytogenetic allow the identification of abnormalities in approxi-
mately 50% of MDS. Some of cytogenetic abnormalities are characteristic of MDS, 
they may be considered as specific to MDS if the clinical context is appropriate 
such del(5q).
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Majority of of MDS (90%) presents somatic mutations, those mutations iden-
tify molecular pathways that drive the pathogenesis of MDS. Even low abundance 
mutations can have prognostic value as they identify emerging clones before they 
impact clinical parameters.
Recent studies demonstrated that 65% of MDS patients harboured mutations 
in RNA splicing (SF3B1, SRSF2, U2AF1, ZRSR2) [28], 47% harbouring mutations 
in DNA methylation genes (DNMT3A, IDH1/2, TET2) [29, 30] and 28% in histone 
modification genes (ASXL1,BCOR, EZH2).
Mutations in isocitrate dehydrogenase 1 or 2 (IDH1 and IDH2) are important to 
identify at the time of diagnosis of high- or very high-risk MDS. These particular 
mutations lead to abnormal leukemogenesis. Mutated IDH1 or IDH2 are not common 
and are only found in approximately 4% to 12% of patients with MDS. Those gene 
mutations have treatment impact. Recently, two IDH inhibitors, specifically ivo-
sidenib targeting IDH1 and enasidenib for IDH2, are approved by the United States 
Food and Drug Administration (FDA) for use in AML, but not in MDS [30, 31].
At present, NGS is rarely incorporated into clinical guidelines although an 
increasing number of studies have demonstrated the benefit of using NGS in the 
clinical management of MDS patients [32].
3.4 Multiple myeloma
Multiple myeloma is a malignant disease characterised by proliferation of 
monoclonal plasma cells leading to clinical features that include hypercalcaemia, 
renal dysfunction, anaemia, and bone disease (frequently referred to by the 
acronym CRAB) which represent evidence of end organ failure.
Recent studies have confirmed that myeloma is an heterogeneous disease com-
posed of multiple molecularly-defined subtypes each with varying clinicopatho-
logical features and disease outcomes [33].
Chromosomal translocations account for 40–50% of primary events in myeloma 
and strongly influence disease phenotype [34].
Karyotypes are complex, hyperploidy can be seen in2/3 of cases, karyotypes can 
change from normal to abnormal during evolution of multiple myoloma.
Fluorescence in situ hybridization (FISH) ssems to be more adequate for recog-
nising specific chromosomal changes in quiescent cells and increases the proportion 
of detection of chromosomal abnormalities in MM up to more than 90% [35].
IG rearrangements: translocations involving 14q32 are found in at least 65–70% 
of patients, most of them result from short segments exchange and are detected 
quite exclusively by FISH.
The (4; 14) is present in 15% of myeloma cases and has been associated with 
a poor prognosis in a variety of clinical settings such as those receiving high dose 
therapy with autologous stem cell transplant (ASCT).
The (11; 14) is observed in approximately 17% of myeloma patients and also 
directly up regulates a cyclin D gene in the form CCND1.
The (6; 14) is a rare translocation occurring in 2% of myeloma patients which 
results in the direct up regulation of the CCND3 gene [36].
Other translocations with IGH involving are reported, but they are rare and it 
seems that they are secondary [37].
Like other haematological neoplasm, multiple myelom benefits from the devel-
opment of molecular technic like NGS, the knowledge about pathogenesis and the 
progression of disease has been improved, with apparition of a new concept called 
subclonality. In fact, NGS characterised the the wide molecular heterogeneity of the 
disease and the frequent occurrence of some supposedly “driver” mutations only in 
subclones. Those found are important for the targeted future therapies [38].
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Figure 2. 
2016 WHO classification of myeloid malignancies.
3.5 Meyloproliferative neoplasm (MPN)
Myeloproliferative neoplasms (MPN) can be denifed by a group of diseases 
characterised by increased proliferation of erythroid, megakaryocytic, or 
granulocytic.
According to WHO (2008) MPN regroups clonal disorders of myeloid pro-
genitor cells., MPN have been classified into 3 groups. Also called Philadelphia 
chromosome-negative (Ph −), myeloproliferative neoplasms (MPNs), include 
polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (both 
primary (PMF) and secondary (post-ET/PV MF)) [39].
The 3 MPN entities are characterised by their clinical heterogeinicity, establish-
ment of precise diagnosis at disease onset can be a real challeng for physician. The 
World Health Organisation (WHO) established revision for diagnostic and defined 
new criteria for MPN on 2016, (Figure 2) [40].
The first gene mutation described in 2005, JAK2-V617F, turned out to be the 
most important and most frequently recurring somatic mutation in MPN [6–9]. The 
frequency ofJAK2-V617F is around 95% in PV and between 50% and 60% in ET and 
PMF [41].
MPN patients who do not present mutations in any of the aforementioned genes 
(so-named “triple-negative” MPN cases), but those patients seem to have hyperac-
tive JAK2 signalling [42].
The JAK2V617F mutation arises in a multipotent haematopoietic progenitor, is 
present in all myeloid lineages.
The JAK2V617F is mainly restricted to classical MPNs with the exception of 
refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T). It can 
rarely be found in some other malignant hemopathies [43, 44].
Concerning MPL mutation, it have been demonstrated that two types of muta-
tion exist: (MPL; the thrombopoietin [TPO] receptor [TPOR]) mutations located in 
exon 10, both have been reported on association with MPNs.
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The most frequent are mutations on the tryptophan W515 located at the bound-
ary of the transmembrane and the cytosolic domains of MPL, the most prominent 
mutations being MPLW515L and K [42].
Mutations on MPLW515 are restricted to ET (around 3%) and PMF 
(around 5%).
At the end of 2013, frameshift mutations in the CALR gene were identified in the 
majority of JAK2− and MPL− ET and PMF (50%–60% ET and 75% PMF).
There are great differences in the frequency between type 1 and type 2 muta-
tions in ET and PMF.
CALR mutations reported are often heterozygous, only few cases of homozy-
gous mutations have been reported, more particularly for type 2 mutations [43].
It has been also proved that CALR mutants gives a stronger clonal advantage when 
compared with JAK2V617F.
In 2010, somatic mutations in exon 2 of LNK (SH2B3), an adaptor protein which 
regulates JAK2 activation, were detected in 2 patients (PMF and ET).
The 3 MPN oncogenes are considered as true drivers of the disease phenotype 
with JAK2 exon 12 giving only an erythrocytosis phenotype, JAK2V617F giving rise 
to ET, PV, and MF, whereas CALR mutant and MPLW515L/K/A are associated with 
ET and MF, resembling the phenotype observed in patients.
The 3 main driver mutations do not explain the entire heterogeneity of the 
classical BCR-ABL− MPNs. The 3 main driver mutations do not explain the entire 
heterogeneity of the classical BCR-ABL− MPNs.
Like other hematologic malignancies, the mutations in epigenetic regulators can 
be observed, such as MDS and AML; and some of the gene mutations, such as TET2 
and ASXL1, are more frequent in MDS than in MPN.
Some studies suggest that the presence of mutations in TET2, EZH2, and ASXL1 
are associated with hight risk of secondary AML.
Few time after the discovery of the JAK2 V617F mutation, multiple small mol-
ecule inhibitors were developed for therapeutic use: ruxolitinib, is the first JAK1 and 
JAK2 inhibitor, approved in August 2011 for use in intermediate and high-risk PMF 
and post PV/ET myelofibrosis.
Selective JAK2 inhibitors, (SAR302503 and BMS911543), combination JAK2/JAK3 
inhibitor (CEP701), and combination JAK2/TYK2 inhibitor (pacritinib) have shown 
clinical efficacy in phase I/II trials.
4. Conclusion
Major progress has been achieved in understanding the molecular pathogenesis 
of haematological malignancies in a very short period of 10 years.
While the clinical utility of this genetic and epigenetic revolution, novel 
therapeutic agents aimed at the aberrant underlying processes are more and more 
included rational combination therapies. This knowledge increase outcome for 
haematological diseases patients, and are helpful to develop therapies based on 
insights into the genetic basis of these haematological neoplasms.
Cytogenetics - Classical and Molecular Strategies for Analysing Heredity Material
10
Author details
Mounia Bendari1*, Sofia Sraidi2 and Nisrine Khoubila2
1 Mohammed VI University of Health Sciences (UM6SS), Casablanca, Morocco
2 Faculty of Medicine and Pharmacy of Casablanca, Hassan II University, 
Casablanca, Morocco
*Address all correspondence to: bendarimounia@gmail.com
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
11
Haematological Malignancies: Overview of the Recent Progresses in Genetics
DOI: http://dx.doi.org/10.5772/intechopen.96913
References
[1] E. Mały. Cytogenetics in 
Hematooncology Recent Trends in 
Cytogenetic Studies–Methodologies 58 
and Applications
[2] Alessandro Gozzetti, michelle M le 
beau. Fluorescence in situ hybridization: 
Uses and limitations November 2000 
Seminars in Hematology 37(4):320-333
[3] Esteban braggio Lessons from 
next-generation sequencing analysis 
in hematological malignancies Blood 
Cancer Journal 3(7):e127
[4] Kobold DC, Steinberg KM, 
Larson DE, Wilson RK, Mardis ER. The 
next generation sequencing revolution 
and its impact on genomics. Cell 2013; 
155:27-38
[5] Yurov YB, Iourov IY, Vorsanova SG, 
et al (2007) Aneuploidy and confi 
ned chromosomal mosaicism in the 
developing human brain. PLoS One 
2(6):e558. D
[6] Yurov YB, Vorsanova SG, Liehr T, 
et al (2014) X chromosome aneuploidy 
in the Alzheimer’s disease brain. Mol 
Cytogenet 7(1):20.
[7] M. Bendari and al, Current 
Cytogenetic Abnormalities in Acute 
Myeloid Leukemia. DOI: http://dx.doi.
org/10.5772/intechopen.91425
[8] Grimwade D, Hills RK, 
Moorman AV, Walker H, Chatters S, 
Goldstone AH, et al. Refinement of 
cytogenetic classification in acute 
myeloid leukemia: Determination 
of prognostic significance of rare 
recurring chromosomal abnormalities 
among 5876 younger adult patients 
treated In the United Kingdom 
Medical Research Council trials. Blood. 
2010;116(3):354-365
[9] Grimwade D, Walker H, Oliver F, et 
al. On behalf of the Medical Research 
Council adult and children’s leukaemia 
working parties. The importance of 
diagnostic Cytogenetics on outcome 
in AML: Analysis of 1612 patients 
entered into the MRC AML10 trial. 
Blood.1998;92(7):2322-2333
[10] Döhner H, Estey E, Grimwade D, 
Amadori S, Appelbaum FR, Büchner T, 
et al. Diagnosis and management of 
AML in adults: 2017 ELN 
recommendations from an international 
expert panel. Blood. 2017;129(4)
[11] Cortes JE, Kantarjian H, Foran JM, 
et al. Phase I study of quizartinib 
administered daily to patients with 
relapsed or refractory acute myeloid 
leukemia irrespective of FMS-like 
tyrosine kinase 3-internal tandem 
duplication status. Journal of Clinical 
Oncology. 2013;31: 3681-3687
[12] Galanis A, Ma H, Rajkhowa T, 
et al. Crenolanib is a potent inhibitor 
of FLT3 with activity against 
resistanceconferring point mutants. 
Blood. 2014;123:94-100
[13] Metzelder SK, Schroeder T, Finck A, 
et al. High activity of Sorafenib in FLT3-
ITD-positive acute myeloid leukemia 
synergizes with allo-immune effects to 
induce sustained responses. Leukemia. 
2012;26:2353-2359
[14] Campo E, and al, The 2008 WHO 
classification of lymphoid neoplasms 
and beyond: evolving concepts and 
practical applications Blood. 2011 May 
12; 117(19): 5019-5032.
[15] Dohner H. Implications of the 
molecular characterization of acute 
myeloid leukemia. Hematology 
2007:412-417.
[16] Peterson L, Bloomfield CD, 
Döhner H, Niemeyer C, Godley L. 
Myeloid neoplasms with germline 
predisposition.
Cytogenetics - Classical and Molecular Strategies for Analysing Heredity Material
12
[17] Swerdlow S, Campo E, Harris NL, et 
al., editors. World Health Organization 
Classification of Tumours of 
Haematopoietic and Lymphoid Tissues. 
4th ed. Lyon, France
[18] Raimondi SC, Pui CH, Head DR, 
Rivera GK, Behm FG. Cytogenetically 
different leukemic clones at relapse 
of childhood acute lymphoblastic 
leukemia. Blood 1993;82:576-580.
[19] Yang JJ, Bhojwani D, Yang W, 
et al. Genome-wide copy number 
profiling reveals molecular evolution 
from diagnosis to relapse in childhood 
acute lymphoblastic leukemia. Blood 
2008;112:4178-4183.
[20] Russell LJ, Capasso M, Vater I, et 
al. Deregulated expression of cytokine 
receptor gene, CRLF2, is involved in 
lymphoid transformation in B-cell 
precursor acute lymphoblastic leukemia. 
Blood 2009;114:2688-2698.
[21] Mullighan CG, 
Collins-Underwood JR, Phillips LA, 
et al. Rearrangement of CRLF2 in 
B-progenitor- and Down syndrome-
associated acute lymphoblastic 
leukemia. Nat Genet 2009;41:1243-1246.
[22] Swerdlow SH, Campo E, Harris NL, 
Jaffe ES, Pileri SA, Stein H, et al., 
editors. WHO classification of tumours 
of haematopoietic and lymphoid tissues. 
Lyon: IARC; 2008.
[23] Deschler B and Lübbert M: Acute 
myeloid leukemia: Epidemiology and 
etiology. Cancer 107: 2099-2107, 2006.
[24] Armstrong SA and Look 
AT: Molecular genetics of acute 
lymphoblastic leukemia. J Clin Oncol 23: 
6306-6315, 2005.
[25] Harrison CJ (2001) Detection 
and significance of chromosomal 
abnormalities in childhood acute 
lymphoblastic leukemia. Blood Rev 
15:49-59 doi:10.1054/blre.2001.0150
[26] Kearney L (1999) The impact 
of new FISH technologies on the 
cytogenetics of the haematological 
malignancies. Br J Haematol 104: 
648-658 doi:10.104
6/j.1365-2141.1999.01181
[27] Graubert TA, Shen D, Ding L, 
Okeyo-Owuor T, Lunn CL, Shao J, et 
al. Recurrent mutations in the U2AF1 
splicing factor in myelodysplastic 
syndromes. Nat Genet. 2011;44:53-57.
[28] Delhommeau F, Dupont S, Valle VD, 
James C, Trannoy S, Massé A, et al. 
Mutation in TET2 in myeloid cancers. 
New Engl J Med. 2009;360:2289-2301.
[29] Mardis ER, Ding L, Dooling DJ, 
Larson DE, McLellan MD, Chen K, 
et al. Recurring mutations found by 
sequencing an acute myeloid leukemia 
genome. N Engl J Med. 2009; 
361:1058-1066.
[30] Gil-Perez A, Montalban-Bravo G. 
Management of myelodysplastic 
syndromes after failure or response 
to hypomethylating agents. Ther Adv 
Hematol. 2019; 10:2040620719847059.
[31] DiNardo CD, Jabbour E, Ravandi F, 
et al. IDH1 and IDH2 mutations in 
myelodysplastic syndromes and role 
in disease progression. Leukemia. 
2016;30(4):980-984.
[32] Tobiasson M A. O. 
Kittang3Treatment of myelodysplastic 
syndrome in the era of next-generation 
sequencing M. 2019 The Association 
for the Publication of the Journal of 
Internal Medicine
[33] Steven M. Prideaux, Emma Conway 
O’Brien, and Timothy J. Chevassut. 
The Genetic Architecture of Multiple 
Myeloma. Advances in Hematology 
2014(6):864058
[34] W. M. Kuehl and P. L. Bergsagel, 
“Early genetic events provide the basis 
for a clinical classification of multiple 
13
Haematological Malignancies: Overview of the Recent Progresses in Genetics
DOI: http://dx.doi.org/10.5772/intechopen.96913
myeloma,” Hematology, pp. 346-
352, 2005.
[35] F. Zhan, Y. Huang, S. Colla et 
al., “The molecular classification of 
multiple myeloma,” Blood, vol. 108, no. 
6, pp. 2020-2028, 2006.
[36] Avet-Loiseau H, Attal M, 
Moreau P, et al. Genetic abnormalities 
and survival in multiple myeloma: 
the experience of the Intergroupe 
Francophone du Myelome. Blood. 
2007;109(8):3489-3495.
[37] J. Corre. Genetics of multiple 
myeloma: another heterogeneity level? 
Blood (2015) 125 (12) : 1870-1876.
[38] James C, Ugo V, Le Couedic JP, 
et al. A unique clonal JAK2 mutation 
leading to constitutive signalling 
causes polycythaemia vera. Nature. 
2005;434:1144-1148.
[39] Baxter EJ, Scott LM, 
Campbell PJ, et al. Acquired mutation 
of the tyrosine kinase JAK2 in human 
myeloproliferative disorders. Lancet. 
2005;365:1054-1061
[40] Arber DA, Orazi A, Hasserjian R, 
et al. The 2016 revision to the World 
Health Organization classification of 
myeloid neoplasms and acute leukemia. 
Blood. 2016;127(20):2391-2405
[41] Rampal R, Al-Shahrour F, 
Abdel-Wahab O, et al. Integrated 
genomic analysis illustrates the central 
role of JAK-STAT pathway activation 
in myeloproliferative neoplasm 
pathogenesis. Blood. 2014;123: 
e123–e133.
[42] Levine RL, Loriaux M,  
Huntly BJ, et al. The JAK2V617F 
activating mutation occurs in chronic 
myelomonocytic leukemia and acute 
myeloid leukemia, but not in acute 
lymphoblastic leukemia or chronic 
lymphocytic leukemia. Blood. 2005;106 
(10):3377-3379.
[43] Pikman Y, Lee B, Mercher T, et al. 
MPLW515L is a novel somatic activating 
mutation in myelofibrosis with myeloid 
metaplasi. PLoS Med. 2006:3 (7):e270.
[44] Klampfl T, Gisslinger H,  
Harutyunyan AS, et al. Somatic 
mutations of calreticulin in  
myeloproliferative neoplasms. N Engl J 
Med. 2013 ;369 (25):2379-2390
